In tumor-adjacent normal tissue, CLDN18.2-postive showed a distinct tumor microenvironment with higher CD4+ FoxP3+ Treg immune cells and CD4+PD-L1+ T cells. This evidence concerns the gene CLDN18 and neoplasm.